198226-65-2

Basic information

• Product Name: Oxirane, [[4-(trifluoromethyl)phenoxy]methyl]-
• Synonyms: 1-(4-trifluoromethylphenoxy)-2,3-epoxypropane;[(4-(trifluoromethyl)phenoxy)methyl]oxirane;2-(4-Trifluoromethyl-phenoxymethyl)-oxirane;4-trifluoromethylphenyl glycidyl ether
• CAS NO: 198226-65-2
• Molecular Formula: C10H9F3O2
• Molecular Weight: 218.175
• Mol File: 198226-65-2.mol
• Article Data: 16

Chemical Properties

• Boiling Point: 145 - 150 °C
• Density: 1.304±0.06 g/cm3(Predicted)
• CAS DataBase Reference: Oxirane, [[4-(trifluoromethyl)phenoxy]methyl]-(CAS DataBase Reference)
• NIST Chemistry Reference: Oxirane, [[4-(trifluoromethyl)phenoxy]methyl]-(198226-65-2)
• EPA Substance Registry System: Oxirane, [[4-(trifluoromethyl)phenoxy]methyl]-(198226-65-2)

Safety Data

• Hazardous Substances Data: 198226-65-2(Hazardous Substances Data)

Upstream product

• 104614-27-9 1-(prop-2-en-1-yloxy)-4-(trifluoromethyl)benzene 
• 402-45-9 4-hydroxybenzotrifluoride 
• 106-89-8 epichlorohydrin 

Downstream Products

• 847344-38-1 1-[2,6-dichloro-4-(3,3-dichloroallyloxy)-phenoxy]-3-(4-trifluoromethylphenoxy)-propan-2-ol 
• 1280193-94-3 1-(((3,5-dimethyl-1-(2-(trifluoromethyl)benzyl)-1H-pyrazol-4-yl)methyl)(methyl)amino)-3-(4-(trifluoromethyl)phenoxy)propan-2-ol 
• 1311146-81-2 1-(((1-(2-chlorobenzyl)-3,5-dimethyl-1H-pyrazol-4-yl)methyl)(methyl)amino)-3-(4-(trifluoromethyl)phenoxy)propan-2-ol 
• 879491-32-4 2-{4-[2-hydroxy-3-(4-trifluoromethyl-phenoxy)-propylsulfanyl]-2-methyl-phenoxy}-2-methyl-propionic acid ethyl ester 
• 851529-15-2 {3-chloro-4-[2-hydroxy-3-(4-trifluoromethyl-phenoxy)-propylsulfanyl]-phenyl}-acetic acid methyl ester 
• 851529-38-9 C₂₀H₂₁F₃O₆ 
• 942066-24-2 3-[(4-(trifluoromethyl)phenoxy)methyl]-4,5-dihydro-isothiazole 1,1-dioxide 
• 851528-78-4 {4-[2-methoxy-3-(4-trifluoromethyl-phenoxy)-propylsulfanyl]-2-methyl-phenoxy}-acetic acid ethyl ester 
• 851529-13-0 {4-[2-(4-butyryl-phenoxy)-3-(4-trifluoromethyl-phenoxy)-propylsulfanyl]-2-methyl-phenoxy}-acetic acid ethyl ester 

Relevant articles and documents

Chemoselective Epoxidation of Allyloxybenzene by Hydrogen Peroxide Over MFI-Type Titanosilicate

The chemoselective synthesis of 2-(phenoxymethyl)oxirane from allyloxybenzene is achieved with over 90 % yield in a sustainable reaction system using titanium-substituted silicalite-1 (TS-1) as a catalyst, hydrogen peroxide (H2O2) as an oxidant, and a mixture of MeOH/MeCN as a solvent at 40 °C. No acid-catalyzed side reactions prompted by the Lewis acidity of the Ti active site in TS-1 are observed. The TS-1 catalyst can also promote the formation of oxiranes from various p-substituted allyloxybenzenes in good yields. The reaction mechanism is investigated through the reaction with other allyloxy compounds. The results, which are supported by DFT calculations, indicate that an active species of Ti peroxides formed from the reaction of TS-1 with H2O2 selectively oxidizes the allyloxybenzene to 2-(phenoxymethyl)oxirane.

Synthesis of 2-(phenoxymethyl)oxirane derivatives through unexpected rearrangement of oxiran-2-ylmethyl benzenesulfonates

The synthesis of 2-(phenoxymethyl)oxirane derivatives from oxiran-2-ylmethyl benzenesulfonates was developed through a base promoted rearrangement. A new C-O bond was formed along with the unexpected cleavage of C-S bond via this process. This unusual reaction was characterized with mild reaction conditions, high efficiency, and excellent functional group tolerance. A plausible reaction mechanism was proposed on the basis of experimental results and control experiments.

Development of β-amino alcohol derivatives that inhibit toll-like receptor 4 mediated inflammatory response as potential antiseptics

Toll-like receptor 4 (TLR4) induced proinflammatory signaling has been directly implicated in severe sepsis and represents an attractive therapeutic target. Herein, we report our investigations into the structure-activity relationship and preliminary drug metabolism/pharmacokinetics study of β-amino alcohol derivatives that inhibit the TLR4 signaling pathway. Lead compounds were identified from in vitro cellular examination with micromolar potency for their inhibitory effects on TLR4 signaling and subsequently assessed for their ability to suppress the TLR4-induced inflammatory response in an ex vivo whole blood model. In addition, the toxicology, specificity, solubility, brain-blood barrier permeability, and drug metabolism of several compounds were evaluated. Although further optimizations are needed, our findings lay the groundwork for the future drug development of this class of small molecule agents for the treatment of severe sepsis.